Bone Abstracts

Background and aims: Bone turnover markers (BTMs) are used in clinical practice for assessing patients with osteoporosis and their treatment. In Spain it is necessary to fine-tune the reference intervals, since they were established years ago in a low number of individuals. The aims of this study were to establish robust reference intervals for BTMs in healthy young premenopausal Spanish women and to investigate the factors influencing BTMs.Methods: 185 ...

Introduction: Osteoporosis is a progressive bone disease characterized by low bone mineral density (BMD), decreased bone strength and increased incidence of fragility fractures. It is one of the major public health conditions, affecting millions of people worldwide. Osteopenia is a potential precursor of osteoporosis and identifying this condition is a pivotal step to institute preventive strategies at younger age, leading to delay in onset or prevention of the disease, thus r...

Background: Zoledronic acid (ZA) is associated with a transient post-infusional acute phase reaction (APR) due to the activation of γδTCR lymphocytes (γδTcells).Aims: To investigate if APR correlates with γδTcell percentage or cytokine polarization, or with 25-OH vitamin D levels; to identify a 25-OH vitamin D level associated with a lower risk of APR.Methods: Sera for ELISA test (IFNγ, IL17, and ...

Objectives: To examine the association of gastrointestinal (GI) events and osteoporosis (OP) therapy initiation patterns among postmenopausal women following a diagnosis of OP from a large health plan in Israel.Methods: Women aged ≥55 years were included in the analysis if they had ≥1 OP diagnosis (ICD-9 733.0X) (date for first OP diagnosis was index date), no estrogen use, no diagnosis of Paget’s disease or malignant neoplasm. OP treatm...

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not d...

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

Background: Atypical fractures (AF) of femoral shaft have distinct radiologic features and are probably related to prolonged bisphosphonate (BP) exposure. They are currently considered to be insufficiency fractures occurring in osteoporotic bone. After initial damage, the repair process calls for accelerated remodeling, but the later is prevented by BP accumulation on the remodeling site. Thus, the fracture expands instead of healing. The management is not postulated, but anab...

Intermittent PTH reduces vertebral fractures risk in osteoporotic patients. The mechanisms trough which PTH acts are not completely understood, it has been observed to activate Wnt pathways in osteoblasts (OBs). Activation of this pathway induces OB proliferation, differentiation and prevents apoptosis. Recently increased expression of Wnt10b by T cells during intermittent PTH, and no increase during continuous PTH has been demonstrated in mice.In order to evaluate if PTH incr...

Osteogenesis imperfect (OI) is an inheritable bone disease with low bone mass, fragility, deformity and multiple fractures in skeletal tissues. Modulation of Wnt signalling components reportedly alleviates excessive bone and joint remodelling in various skeletal disorders. This study is undertaken to explore whether loss of Wnt inhibitor Dickkopf-1 (Dkk1) action affects bone formation or skeletal homeostasis in OI. In clinical vignettes, OI patients had severe osteoporosis (<e...

Glucocorticoids (GCs) are widely used to treat chronic inflammatory diseases such as rheumatoid (RA) and lead to multiple side effects including glucocorticoid induced osteoporosis (GIO). Our work challenges the dogma that transrepression of pro-inflammatory genes by the glucocorticoid receptor (GR) is solely responsible for reducing inflammation, whereas transactivation of genes is causing side effects.Using conditional and function selective mutant mic...